N-(Pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

2,000.00

CAS No. 1383385-64-5
Application Acalabrutinib
Synonyms 4-(2-Pyridylcarbamoyl)phenylboronic Acid Pinacol Ester, N-(pyridin-2-yl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
Status Kilo Lab Scale

Description

N-(Pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (CAS No. 1383385-64-5)

N-(Pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (CAS No. 1383385-64-5) is an important pharmaceutical intermediate used in the production of Acalabrutinib, that is a drug designed to treat certain cancers. As a trusted 1383385-64-5 manufacturer in India, we ensure that this compound meets the highest standards of quality. It plays a vital role in the synthesis of Acalabrutinib. It is primarily used in pharmaceutical research and development. This intermediate is soluble in organic solvents like methanol and chloroform. Its stable nature and reactivity make it essential for the development of Acalabrutinib and other related pharmaceutical formulations.

Why Choose Punagri?

Manufactured to the Highest Standards
As a trusted 1383385-64-5 manufacturer in Vapi, Punagri is committed to maintaining the highest quality and safety standards in every batch of Acalabrutinib intermediate we produce. We make sure that all products are manufactured following strict procedures to meet global pharmaceutical requirements.

Quality You Can Count On
Our comprehensive quality control processes guarantee that each batch is pure, consistent, and reliable. We also offer you the confidence that your production will meet the highest standards.

Tailored to Your Needs
We offer flexible batch sizes and customized solutions to meet your specific needs. Whether for research or large-scale production. We provide the precise intermediates required for your pharmaceutical processes.

On-Time Delivery
With our efficient supply chain, we make sure that deliveries are made on time. We help you meet production schedules and regulatory deadlines without delay.

Additional information

Application Area

Acalabrutinib